2016
DOI: 10.1212/wnl.0000000000003004
|View full text |Cite
|
Sign up to set email alerts
|

Neuromuscular endplate pathology in recessive desminopathies

Abstract: The patients were desmin-null and had myopathy, cardiomyopathy, and a congenital myasthenic syndrome. The data from man and mouse demonstrate that the complete lack as well as the markedly decreased expression of mutant R349P desmin impair the structural and functional integrity of neuromuscular endplates.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

3
34
0

Year Published

2016
2016
2023
2023

Publication Types

Select...
6
1
1

Relationship

2
6

Authors

Journals

citations
Cited by 27 publications
(37 citation statements)
references
References 15 publications
3
34
0
Order By: Relevance
“…While the vast majority of desminopathies show an autosomal-dominant trait of inheritance and displays morphological signs of protein aggregation pathology in striated muscle, the very rare autosomal-recessive cases can meanwhile be categorized in three distinct subforms: (1) one with the complete absence of desmin protein and no obvious protein aggregation pathology [4][5][6][7], (2) one with markedly reduced protein levels of solely mutant desmin without signs of protein aggregation [8], and (3) one with markedly reduced protein levels of solely mutant desmin but the presence of protein aggregation [9][10][11][12][13]. In contrast to the autosomaldominant cases, these recessive forms display a markedly more severe clinical phenotype and an earlier disease onset already starting in the first or second decade of life.…”
Section: Introductionmentioning
confidence: 99%
“…While the vast majority of desminopathies show an autosomal-dominant trait of inheritance and displays morphological signs of protein aggregation pathology in striated muscle, the very rare autosomal-recessive cases can meanwhile be categorized in three distinct subforms: (1) one with the complete absence of desmin protein and no obvious protein aggregation pathology [4][5][6][7], (2) one with markedly reduced protein levels of solely mutant desmin without signs of protein aggregation [8], and (3) one with markedly reduced protein levels of solely mutant desmin but the presence of protein aggregation [9][10][11][12][13]. In contrast to the autosomaldominant cases, these recessive forms display a markedly more severe clinical phenotype and an earlier disease onset already starting in the first or second decade of life.…”
Section: Introductionmentioning
confidence: 99%
“…Rare cases of recessive myopathies have also been described with loss‐of‐function variants in DES . Two such patients additionally displayed evidence of impaired neuromuscular transmission . Both presented in infancy with delayed motor milestones and progressive generalized weakness, ptosis, and ophthalmoparesis.…”
Section: Hereditary Muscle Diseases With Neuromuscular Transmission Dmentioning
confidence: 98%
“…Salbutamol was effective in one patient, while pyridostigmine was ineffective in the other. A deleterious effect of desmin loss on neuromuscular junction integrity was demonstrated in mice homozygous for a common missense mutation in Des …”
Section: Hereditary Muscle Diseases With Neuromuscular Transmission Dmentioning
confidence: 99%
“…The deleterious effects of abnormal desmin IF networks, due to either the additional presence of mutant or the complete lack of wild-type desmin protein, are emphasized by the group of human desminopathies that comprise autosomal-dominantly and recessively inherited myopathies and cardiomyopathies Clemen et al (2013) . Human desminopathies are clinically characterized by a broad phenotypic variability ranging from primary distal myopathies, limb girdle muscular dystrophies and scapuloperoneal syndromes to generalized myopathies Walter et al (2007); Baer (2005); Clemen et al (2009); Durmuş et al (2016) . The major problem with elucidating pathophysiological mechanisms of the human phenotypes is that knowledge about early and intermediate stages of the disease is usually elusive, since muscle tissue specimens for research are not available from patients at pre-clinical stages.…”
Section: Introductionmentioning
confidence: 99%